Randomized Trialhigh evidence
Responsive stimulation of the thalamus for idiopathic generalized epilepsy: Results of the randomized controlled NAUTILUS trial through 18 months.
Epilepsia·June 3, 2026·PMID 42233958
Why it mattersThis is the first randomized controlled neuromodulation trial in IGE, providing evidence for a new adjunctive therapy option in a population with limited treatment alternatives. The durable seizure reductions and high patient-reported improvement suggest meaningful clinical benefit despite the primary endpoint miss.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled